“Cancer-Free”: the two happiest and most hopeful words a patient can hear.
Toronto-based drug maker Theralase Technologies Inc. (TSX-Venture:TLT) was able to hear a patient’s doctors utter those words recently. The clinical stage pharmaceutical dedicated to the research and development of light activated Photo Dynamic Compounds to attack and destroys cancer cells, reported that one patient in a recent clinical study has demonstrated a CR with no tumour recurrence, progression or presence of NMIBC disease at the 360-day clinical and cystoscopy assessment.
The study's purpose was to evaluate TLD-1433, Theralase's lead PDC, for the primary endpoint of safety and tolerability, a secondary endpoint of pharmacokinetics (movement and exit of drug within tissue) and exploratory endpoint of efficacy, primarily at 90 days and secondarily at 180 days post treatment.
The study was successfully completed with two of the patients five and six demonstrating achievement of the primary, secondary and exploratory endpoints at 90 and 180 days, when treated with the Therapeutic Dose.
Shares in TLT catapulted 4.5 cents, or 9.3%, late Tuesday morning, to 53 cents, on volume of 579,000 shares.
